HC Wainwright Predicts Increased Earnings for Co-Diagnostics

Co-Diagnostics, Inc. (NASDAQ:CODX) – HC Wainwright lifted their FY2024 EPS estimates for Co-Diagnostics in a research report issued on Monday, November 11th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($1.22) per share for the year, up from their previous estimate of ($1.23). HC Wainwright has a “Neutral” rating and a $1.50 price target on the stock. The consensus estimate for Co-Diagnostics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Co-Diagnostics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.17) EPS.

Co-Diagnostics Trading Down 3.6 %

CODX stock opened at $1.06 on Thursday. The company’s 50 day moving average is $1.23 and its 200 day moving average is $1.25. The stock has a market cap of $33.85 million, a price-to-earnings ratio of -0.77 and a beta of -0.84. Co-Diagnostics has a 1-year low of $1.00 and a 1-year high of $2.23.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Co-Diagnostics stock. Jane Street Group LLC purchased a new position in Co-Diagnostics, Inc. (NASDAQ:CODX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 44,124 shares of the company’s stock, valued at approximately $55,000. Jane Street Group LLC owned 0.14% of Co-Diagnostics as of its most recent SEC filing. 14.99% of the stock is owned by hedge funds and other institutional investors.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.